← All trials
NCT06363994
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 25, 2024
- Primary completion
- Dec 25, 2034
- Completion date
- Dec 25, 2035
- First posted
- Apr 12, 2024
- Last posted
- Apr 12, 2024
- Enrollment
- 490
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Beijing InnoCare Pharma Tech Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.